Complete Filing Data
MapLight Therapeutics, Inc. reported Stockholders Equity of $458.37 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean MapLight Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Net Income Loss | -$161.2M | -$77.6M |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -$391.0K | $163.0K |
| Research And Development Expense | $138.3M | $68.5M |
| Other Nonoperating Income Expense | $2.4M | $1.8M |
| Operating Income Loss | -$169.1M | -$82.9M |
| Operating Expenses | $169.1M | $82.9M |
| Nonoperating Income Expense | $7.9M | $5.4M |
| General And Administrative Expense | $30.7M | $14.4M |
| Comprehensive Income Net Of Tax | -$161.5M | -$77.4M |
| Deferred Revenue Current | $0.00 | $3.2M |
| Other Income Loss From Equity Method Investment | -$986.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income Loss | -$29.4M | -$29.8M | -$22.3M | -$19.0M | -$18.4M | -$18.9M |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -$4.0K | -$35.0K | -$78.0K | $613.0K | -$185.0K | |
| Research And Development Expense | $27.1M | $16.8M | ||||
| Other Nonoperating Income Expense | $531.0K | $797.0K | ||||
| Operating Income Loss | -$31.5M | -$20.9M | ||||
| Operating Expenses | $31.5M | $20.9M | ||||
| Nonoperating Income Expense | $2.1M | $1.9M | ||||
| General And Administrative Expense | $4.4M | $4.1M | ||||
| Comprehensive Income Net Of Tax | -$29.4M | -$18.4M | ||||
| Deferred Revenue Current | $1.2M | |||||
| Other Income Loss From Equity Method Investment |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stockholders Equity | $458.4M | -$193.6M | -$117.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $46.9M | $38.5M | $80.0M |
| Short Term Investments | $258.4M | $70.5M | |
| Retained Earnings Accumulated Deficit | -$360.5M | -$199.4M | |
| Restricted Cash Noncurrent | $207.0K | $207.0K | |
| Property Plant And Equipment Net | $1.1M | $1.2M | |
| Prepaid Expense And Other Assets Current | $19.6M | $5.8M | |
| Other Assets Noncurrent | $59.0K | $3.2M | |
| Operating Lease Right Of Use Asset | $5.5M | $6.4M | |
| Operating Lease Liability Noncurrent | $4.9M | $5.8M | |
| Operating Lease Liability Current | $891.0K | $778.0K | |
| Noncash Lease Expense | $866.0K | $745.0K | |
| Liabilities Current | $16.2M | $15.9M | |
| Liabilities And Stockholders Equity | $479.5M | $136.9M | |
| Liabilities | $21.1M | $21.7M | |
| Common Stock Value | $5.0K | $0.00 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $8.5M | -$41.5M | |
| Cash And Cash Equivalents At Carrying Value | $46.7M | $38.3M | |
| Assets Current | $324.7M | $114.6M | |
| Assets | $479.5M | $136.9M | |
| Additional Paid In Capital Common Stock | $819.1M | $5.6M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$228.0K | $163.0K | |
| Accrued Liabilities Current | $12.0M | $10.0M | |
| Accretion Amortization Of Discounts And Premiums Investments | $2.1M | $1.7M | |
| Accounts Payable Current | $3.3M | $1.9M | |
| Long Term Investments | $148.0M | $11.4M | |
| Gain Loss On Sale Of Property Plant Equipment | -$7.0K | -$59.0K | |
| Deferred Financing Costs Included In Accounts Payable And Accrued Expenses | $848.0K | ||
| Stock Issued During Period Value Purchase Of Assets | $496.0K | ||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $1.5M | ||
| Purchase Of Property And Equipment Included In Accounts Payable And Accrued Expenses | $226.0K | ||
| Liabilities Noncurrent | |||
| Equity Method Investment Realized Gain Loss On Disposal | -$986.0K | ||
| Common Stock Issued In Asset Purchase Agreement | $496.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$274.2M | -$245.1M | -$215.8M | -$172.4M | -$154.3M | -$136.0M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $64.4M | $27.5M | |||||
| Short Term Investments | $163.0M | ||||||
| Retained Earnings Accumulated Deficit | -$281.0M | ||||||
| Restricted Cash Noncurrent | $207.0K | ||||||
| Property Plant And Equipment Net | $859.0K | ||||||
| Prepaid Expense And Other Assets Current | $18.1M | ||||||
| Other Assets Noncurrent | $5.1M | ||||||
| Operating Lease Right Of Use Asset | $5.7M | ||||||
| Operating Lease Liability Noncurrent | $5.1M | ||||||
| Operating Lease Liability Current | $862.0K | ||||||
| Noncash Lease Expense | |||||||
| Liabilities Current | $18.6M | ||||||
| Liabilities And Stockholders Equity | $257.2M | ||||||
| Liabilities | $23.7M | ||||||
| Common Stock Value | $0.00 | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | |||||||
| Cash And Cash Equivalents At Carrying Value | $64.1M | ||||||
| Assets Current | $245.3M | ||||||
| Assets | $257.2M | ||||||
| Additional Paid In Capital Common Stock | $6.7M | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $46.0K | ||||||
| Accrued Liabilities Current | $14.0M | ||||||
| Accretion Amortization Of Discounts And Premiums Investments | |||||||
| Accounts Payable Current | $2.4M | ||||||
| Long Term Investments | |||||||
| Gain Loss On Sale Of Property Plant Equipment | |||||||
| Deferred Financing Costs Included In Accounts Payable And Accrued Expenses | |||||||
| Stock Issued During Period Value Purchase Of Assets | $496.0K | ||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | |||||||
| Purchase Of Property And Equipment Included In Accounts Payable And Accrued Expenses | |||||||
| Liabilities Noncurrent | $5.1M | $5.8M | |||||
| Equity Method Investment Realized Gain Loss On Disposal | |||||||
| Common Stock Issued In Asset Purchase Agreement |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $36.0M | $1.1M |
| Share Based Compensation | $36.0M | $1.1M |
| Proceeds From Stock Options Exercised | $285.0K | $294.0K |
| Proceeds From Sale And Maturity Of Marketable Securities | $85.5M | $45.0M |
| Payments To Acquire Property Plant And Equipment | $473.0K | $770.0K |
| Payments To Acquire Investments | $408.2M | $125.0M |
| Payments Of Financing Costs | $5.0M | $2.2M |
| Net Cash Provided By Used In Operating Activities | -$138.1M | -$78.8M |
| Net Cash Provided By Used In Investing Activities | -$323.2M | -$80.8M |
| Net Cash Provided By Used In Financing Activities | $469.8M | $118.1M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $13.1M | $2.3M |
| Increase Decrease In Operating Lease Liability | -$777.0K | -$653.0K |
| Increase Decrease In Deferred Grant Earnings | -$3.2M | -$959.0K |
| Increase Decrease In Accrued Liabilities | $2.9M | $2.2M |
| Increase Decrease In Accounts Payable | $1.4M | -$1.3M |
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock And Preferred Stock Purchase Right Net Of Issuance Cost | $120.0M | |
| Proceeds From Issuance Of Convertible Preferred Stock | $198.8M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $125.0K | $148.0K | $212.0K | $354.0K | $245.0K | $267.0K |
| Share Based Compensation | ||||||
| Proceeds From Stock Options Exercised | ||||||
| Proceeds From Sale And Maturity Of Marketable Securities | ||||||
| Payments To Acquire Property Plant And Equipment | ||||||
| Payments To Acquire Investments | ||||||
| Payments Of Financing Costs | ||||||
| Net Cash Provided By Used In Operating Activities | ||||||
| Net Cash Provided By Used In Investing Activities | ||||||
| Net Cash Provided By Used In Financing Activities | ||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | ||||||
| Increase Decrease In Operating Lease Liability | ||||||
| Increase Decrease In Deferred Grant Earnings | ||||||
| Increase Decrease In Accrued Liabilities | ||||||
| Increase Decrease In Accounts Payable | ||||||
| Proceeds From Issuance Of Redeemable Convertible Preferred Stock And Preferred Stock Purchase Right Net Of Issuance Cost | ||||||
| Proceeds From Issuance Of Convertible Preferred Stock |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 8.7M | 736.2K |
| Weighted Average Number Of Diluted Shares Outstanding | 8.7M | 736.2K |
| Earnings Per Share Diluted | $-18.56 | $-105.38 |
| Earnings Per Share Basic | $-18.56 | $-105.38 |
| Common Stock Shares Outstanding | 44.0M | 761.3K |
| Common Stock Shares Issued | 44.0M | 761.3K |
| Common Stock Shares Authorized | 500.0M | 325.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
| Preferred Stock Shares Authorized | 10.0M | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 791.1K | 758.2K |
| Weighted Average Number Of Diluted Shares Outstanding | 791.1K | 758.2K |
| Earnings Per Share Diluted | $-37.18 | $-25.08 |
| Earnings Per Share Basic | $-37.18 | $-25.08 |
| Common Stock Shares Outstanding | 808.0K | |
| Common Stock Shares Issued | 808.0K | |
| Common Stock Shares Authorized | 1.47B | |
| Common Stock Par Or Stated Value Per Share | $0.00 | |
| Preferred Stock Shares Authorized | ||
| Preferred Stock Par Or Stated Value Per Share | ||
| Preferred Stock Shares Outstanding | ||
| Preferred Stock Shares Issued |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $285.0K | $294.0K |
| Investment Income Interest | $5.5M | $4.5M |
| Depreciation | $578.0K | $701.0K |
| Stock Issued During Period Value New Issues | $269.1M | |
| Stock Issued During Period Value Conversion Of Convertible Securities | $507.7M | |
| Stock Issued During Period Shares Stock Options Exercised | 42.5K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $183.0K | $3.0K | $5.0K | $7.0K | $9.0K | $256.0K |
| Investment Income Interest | $1.5M | $1.1M | ||||
| Depreciation | $100.0K | $200.0K | ||||
| Stock Issued During Period Value New Issues | ||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | ||||||
| Stock Issued During Period Shares Stock Options Exercised |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.